Dysplasia detection rates under a surveillance program in a tertiary referral center for inflammatory bowel diseases: Real-world data
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.10.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Yifat Snir und 10 weiteren Autor:innen. Beteiligte Einrichtung: IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Isra…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colorectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Surveillance colonoscopies are crucial for high-risk patients with inflammatory bowel diseases (IBD) to detect colorectal carcinoma (CRC). However, there is no established quality metric for dysplasia detection rate (DDR) in IBD surveillance. This study assessed the DDR in a dedicated surveillance program at a tertiary referral center for IBD. METHODS: Consecutive patients with quiescent colitis were enrolled in a cross-sectional study evaluating DDR. High-definition colonoscopy with dye chromoendoscopy (DCE) was performed by a specialized operator. Advanced dysplasia (AD) was defined as low-grade dysplasia ≥ 10 mm, high-grade dysplasia, or colorectal cancer. Risk factors for dysplasia detection were analyzed. RESULTS: In total, 119 patients underwent 151 procedures, identifying 206 lesions, of which 40 dysplastic with seven AD . Per-lesion and per-procedure DDR were 19.4 % and 20.5 %, respectively. The per-procedure AD detection rate (ADDR) was 4.6 %. A Kudo pit pattern of II-V had a sensitivity of 92.5 % for dysplasia detection but a false positive rate of 64.8 % (p < 0.001). Age at diagnosis and at index colonoscopy and past or indefinite dysplasia were associated with per-procedure dysplasia detection. CONCLUSIONS: In a real-world setting, a dedicated surveillance program achieved a high DDR. We suggest that optimal DDR in high-risk IBD patients be defined and implemented as a standardized quality measure for surveillance programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: henityanai@gmail.com.
Zitieren
APA
Snir, Y., Ollech, J. E., Peleg, N., Avni-Biron, I., Eran-Banai, H., Broitman, Y., Sharar-Fischler, T., Goren, I., Levi, Z., Dotan, I., & Yanai, H. (2024). Dysplasia detection rates under a surveillance program in a tertiary referral center for inflammatory bowel diseases: Real-world data. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.10.001
Vancouver
Snir Y, Ollech JE, Peleg N, Avni-Biron I, Eran-Banai H, Broitman Y, et al. Dysplasia detection rates under a surveillance program in a tertiary referral center for inflammatory bowel diseases: Real-world data. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.10.001
BibTeX
@article{Snir2024,
author = {Snir, Yifat and Ollech, Jacob E and Peleg, Noam and Avni-Biron, Irit and Eran-Banai, Hagar and Broitman, Yelena and Sharar-Fischler, Tali and Goren, Idan and Levi, Zohar and Dotan, Iris and Yanai, Henit},
title = {Dysplasia detection rates under a surveillance program in a tertiary referral center for inflammatory bowel diseases: Real-world data},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.10.001}
}
EUVIMED